Accretive Health was downgraded to sell from hold by TheStreet Ratings on Wednesday. TheStreet Ratings gives Accretive Health a D+ grade. The stock closed Friday at $10.86 and has fallen 52.74% year to date.
It may be a second-tier brand, but it is still a profitable one that also happens to be asset-rich.
Ruby Tuesday CEO James Buettgen is resigning from the company effective immediately, as the company reported lower-than-expected preliminary fiscal 2017 first quarter results.